Search

Novo Nordisk A-S (Class B)

Gesloten

334.55 0.75

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

331.3

Max

338.7

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.5B

27B

Verkoop

-1.2B

77B

K/W

Sectorgemiddelde

13.622

37.003

EPS

5.96

Dividendrendement

3.41

Winstmarge

34.484

Werknemers

78,387

EBITDA

44B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.41%

2.25%

Volgende Winsten

5 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

126B

1.5T

Vorige openingsprijs

333.8

Vorige sluitingsprijs

334.55

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 okt 2025, 10:26 UTC

Belangrijke Marktbewegers

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17 okt 2025, 10:25 UTC

Belangrijke Marktbewegers

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 okt 2025, 15:36 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 okt 2025, 13:27 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9 okt 2025, 10:49 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1 okt 2025, 08:54 UTC

Belangrijke Marktbewegers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22 okt 2025, 10:45 UTC

Winsten

AI Stocks Aren't the Only Market Play. How -2-

22 okt 2025, 10:45 UTC

Winsten

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17 okt 2025, 10:10 UTC

Belangrijke Marktbewegers

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 okt 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10 okt 2025, 16:19 UTC

Acquisities, Fusies, Overnames

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 okt 2025, 13:03 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9 okt 2025, 15:17 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9 okt 2025, 11:31 UTC

Acquisities, Fusies, Overnames

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9 okt 2025, 10:34 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9 okt 2025, 10:07 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9 okt 2025, 10:05 UTC

Acquisities, Fusies, Overnames

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9 okt 2025, 10:04 UTC

Acquisities, Fusies, Overnames

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9 okt 2025, 10:03 UTC

Acquisities, Fusies, Overnames

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9 okt 2025, 10:01 UTC

Acquisities, Fusies, Overnames

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7 okt 2025, 09:15 UTC

Marktinformatie

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1 okt 2025, 09:05 UTC

Populaire aandelen

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sep 2025, 12:04 UTC

Marktinformatie

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sep 2025, 13:43 UTC

Acquisities, Fusies, Overnames

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sep 2025, 12:30 UTC

Marktinformatie

Correction to Novo Nordisk Market Talk

18 sep 2025, 12:00 UTC

Marktinformatie

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sep 2025, 08:55 UTC

Populaire aandelen

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK  9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat